Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The ideal inhaler for asthma therapy.

H Buck1

  • 1Innovata Biomed Ltd, St Albans, UK. hbuck@innovatabiomed.com

Medical Device Technology
|August 27, 2003
PubMed
Summary

New multidose nebulisers and dry-powder inhalers are emerging due to new drugs and generic availability. This article outlines the essential characteristics of an ideal inhaler device for optimal drug delivery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Studies with recent type O FMD isolates from South-East Asia.

Revue scientifique et technique (International Office of Epizootics)·2020
Same author

Bioavailability of budesonide delivered by the clickhaler® and turbuhaler® dry powder inhalers in healthy volunteers : a pilot study.

Clinical drug investigation·2013
Same author

Biocompatibility of an electrochemical sensor for continuous glucose monitoring in subcutaneous tissue.

Diabetes technology & therapeutics·2005
Same author

Acute radiation toxicity assessment of a 3-D conformal head and neck radiation treatment technique.

Australasian radiology·2004
Same author

Assessment of adrenal suppression from two new dry powder inhaler formulations of budesonide delivered by Clickhaler compared with the Pulmicort Turbuhaler.

Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine·2003
Same author

Discriminating measures of bronchodilator drug efficacy and potency.

British journal of clinical pharmacology·2001

Area of Science:

  • Pharmaceutical Technology
  • Drug Delivery Systems
  • Respiratory Medicine

Background:

  • Advancements in novel chemical entities and generic drug availability are driving innovation in inhalation devices.
  • Conventional metered-dose inhalers (MDIs) are being phased out due to environmental regulations on chlorofluorocarbon (CFC) propellants.
  • The need for efficient and reliable drug delivery via inhalation is paramount in respiratory care.

Purpose of the Study:

  • To identify and discuss the critical features of an ideal inhaler device.
  • To provide a comprehensive overview of current innovations in nebuliser and dry-powder inhaler technology.
  • To guide the selection and development of next-generation inhalation devices.

Main Methods:

  • Literature review of recent advancements in nebuliser and dry-powder inhaler technologies.
  • Analysis of key performance indicators for inhaler devices, including dose uniformity, particle size distribution, and user-friendliness.
  • Synthesis of information on regulatory requirements and market trends influencing inhaler design.

Main Results:

  • Key features of ideal inhalers include precise dose delivery, optimal aerosol/particle characteristics, and ease of use.
  • Emerging technologies focus on breath-actuated mechanisms and improved formulation compatibility.
  • The transition away from CFCs necessitates the adoption of new propellant systems or alternative device types.

Conclusions:

  • The ideal inhaler must balance technological innovation with patient needs and environmental considerations.
  • Future inhaler development will likely focus on smart devices with integrated monitoring capabilities.
  • Optimizing inhaler design is crucial for enhancing therapeutic outcomes in respiratory diseases.

Related Experiment Videos